News

Update on the DIAN-TU-001 Trial with E2814 and Lecanemab (Eisai Co., Ltd)

The statement below is in response to Eisai’s 06 January 2023 announcement regarding the FDA’s accelerated approval of lecanemab for...

FDA APPROVES LEQEMBI™ (LECANEMAB-IRMB) UNDER THE ACCELERATED APPROVAL PATHWAY FOR THE TREATMENT OF ALZHEIMER’S DISEASE

Eisai Co., Ltd. - Jan 06 2023

Update on the DIAN-TU-002 Primary Prevention Trial

20 December 2022 Update on the DIAN-TU-002 Primary Prevention Trial The statement below is an update to the 15 November...

WashU, Eisai form drug discovery collaboration

The Source, Washington University in St. Louis - Dec 14, 2022

Update on the DIAN-TU-001 Open Label Extension and DIAN-TU-002 Primary Prevention Trials with Gantenerumab (Roche/Genentech)

The statement below is in response to the 14 November 2022 announcement regarding the results from the GRADUATE I and...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease

Roche - Nov 14, 2022

Update on the DIAN-TU-001 Trial with E2814 and Investigational Lecanemab (Eisai Co., Ltd)

The statement below is in response to the 28 September 2022 announcement found on Eisai’s website. Eisai Co., Ltd. (Headquarters:...

LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE

Eisai Co., Ltd. - Sept 27 2022

Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease

F. Hoffmann-La Roche Ltd - June 16, 2022

Could drugs prevent Alzheimer’s? These trials aim to find out

Nature - Mar 9, 2022